$0.03 EPS Expected for Harvard Bioscience, Inc. (NASDAQ:HBIO) This Quarter

Wall Street brokerages forecast that Harvard Bioscience, Inc. (NASDAQ:HBIO) will report $0.03 earnings per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Harvard Bioscience’s earnings. Harvard Bioscience posted earnings of ($0.01) per share in the same quarter last year, which would suggest a positive year over year growth rate of 400%. The company is scheduled to report its next quarterly earnings results on Tuesday, May 4th.

On average, analysts expect that Harvard Bioscience will report full year earnings of $0.23 per share for the current financial year. For the next financial year, analysts forecast that the firm will report earnings of $0.35 per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Harvard Bioscience.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings results on Tuesday, March 9th. The medical instruments supplier reported $0.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.04. The company had revenue of $30.98 million for the quarter, compared to analyst estimates of $27.15 million. Harvard Bioscience had a negative net margin of 6.51% and a positive return on equity of 4.29%.

Several equities analysts have issued reports on the stock. KeyCorp increased their price objective on shares of Harvard Bioscience from $6.00 to $9.00 in a report on Wednesday, March 10th. Benchmark raised shares of Harvard Bioscience from a “speculative buy” rating to a “buy” rating in a report on Thursday, January 7th. Zacks Investment Research downgraded shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, April 1st. Finally, Northland Securities initiated coverage on shares of Harvard Bioscience in a research note on Wednesday, December 9th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Harvard Bioscience has a consensus rating of “Buy” and an average target price of $7.50.

HBIO opened at $6.28 on Monday. The company has a quick ratio of 0.98, a current ratio of 2.05 and a debt-to-equity ratio of 0.53. The company has a market cap of $250.11 million, a price-to-earnings ratio of -34.89 and a beta of 1.73. Harvard Bioscience has a 52-week low of $2.06 and a 52-week high of $7.14. The firm’s fifty day simple moving average is $5.25 and its two-hundred day simple moving average is $4.25.

In other Harvard Bioscience news, CEO James W. Green sold 35,000 shares of the business’s stock in a transaction that occurred on Friday, March 12th. The shares were sold at an average price of $5.98, for a total transaction of $209,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.40% of the company’s stock.

Several large investors have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Harvard Bioscience by 5.4% during the 4th quarter. BlackRock Inc. now owns 2,953,905 shares of the medical instruments supplier’s stock worth $12,673,000 after buying an additional 151,549 shares during the last quarter. Royce & Associates LP lifted its position in shares of Harvard Bioscience by 4.5% during the 4th quarter. Royce & Associates LP now owns 1,665,600 shares of the medical instruments supplier’s stock worth $7,145,000 after buying an additional 71,875 shares during the last quarter. Punch & Associates Investment Management Inc. lifted its position in shares of Harvard Bioscience by 4.8% during the 4th quarter. Punch & Associates Investment Management Inc. now owns 1,611,835 shares of the medical instruments supplier’s stock worth $6,915,000 after buying an additional 74,035 shares during the last quarter. State Street Corp lifted its position in shares of Harvard Bioscience by 11.1% during the 3rd quarter. State Street Corp now owns 464,325 shares of the medical instruments supplier’s stock worth $1,398,000 after buying an additional 46,466 shares during the last quarter. Finally, Greenwood Capital Associates LLC lifted its position in shares of Harvard Bioscience by 39.1% during the 4th quarter. Greenwood Capital Associates LLC now owns 207,718 shares of the medical instruments supplier’s stock worth $891,000 after buying an additional 58,376 shares during the last quarter. Institutional investors and hedge funds own 64.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

Featured Story: Gross Domestic Product (GDP)

Get a free copy of the Zacks research report on Harvard Bioscience (HBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.